Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PTPRA | P18433 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL741038 | 0.84 | PARP10 (0.56) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL9719810 | 0.81 | RAB9A (0.65) | SMN1; SMN2NPC1RAB9ALMNACYP1A2 | |
| SCHEMBL493397 | 0.80 | HRH1 (0.52) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL18997786 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL740907 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL19212962 | 0.79 | KMT2A (0.49) | LMNAALOX15KMT2AKDM4EALDH1A1 | |
| SCHEMBL7189404 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| Hydrochloric Acid SCHEMBL27710379 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL11377704 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL8228259 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ALMNAPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| CN-103097340-A | Therapeutically active compositions and methods of use thereof | AGIOS PHARMACEUTICALS INC | 2013-05-08 | — | — | CN | disclosed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-6518285-B2 | 4-oxo-5-oxazolidineylmethyl derivatives; antibacterials which are active against numerous multidrug-resistant gram positive organisms | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-1246810-A1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020103377-A1 | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-01 | — | — | US | disclosed |
| EP-0928793-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2002-05-15 | — | — | EP | disclosed |
| WO-2002030897-A2 | COMPOSITIONS AND METHODS FOR REGULATING THE NERVOUS SYSTEM | FILLION GILLES (FR) | 2002-04-18 | — | — | WO | disclosed |
| EP-1173455-A2 | NOVEL RIBOSE-SUBSTITUTED AROMATIC AMIDES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Aventis Pharma S.A. (FR) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001046164-A1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2000063222-A2 | NOVEL RIBOSE-SUBSTITUTED AROMATIC AMIDES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA S.A. (FR) | 2000-10-26 | — | — | WO | disclosed |
| US-6001855-A | REACTING A THIAZOLE DERIVATIVE AND A CYCLIC AMINE DERIVATIVE; INHIBITS BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES OF CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS | HOFFMAN-LA ROCHE INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0928793-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | SMN1; SMN2 166/4885NPC1 2594/4885RAB9A 1278/4885 |
| US-20020103377-A1 | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials | OXA1L, RPS27L, RPS27 | SMN1; SMN2 3906/4885NPC1 2994/4885RAB9A 831/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | SMN1; SMN2 166/4885NPC1 2594/4885RAB9A 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.